EP Patent

EP2127655A1 — Use of loteprednol etabonate for the treatment of dry eye

Assigned to Bausch and Lomb Inc · Expires 2009-12-02 · 16y expired

What this patent protects

Disclosed in embodiments herein is a method of treating chronic dry eye in a patient in need thereof, the method comprising topically administering to the patient Loteprednol etabonate in an ophthalmolically acceptable carrier.

USPTO Abstract

Disclosed in embodiments herein is a method of treating chronic dry eye in a patient in need thereof, the method comprising topically administering to the patient Loteprednol etabonate in an ophthalmolically acceptable carrier.

Drugs covered by this patent

Patent Metadata

Patent number
EP2127655A1
Jurisdiction
EP
Classification
—
Expires
2009-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Bausch and Lomb Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.